CAIX Inhibitor S4 manufacturers
- CAIX Inhibitor S4
-
- $34.00 / 2mg
-
2026-01-05
- CAS:1330061-67-0
- Min. Order:
- Purity: 99.07%
- Supply Ability: 10g
- S4
-
- $1.00 / 1g
-
2024-09-29
- CAS:1330061-67-0
- Min. Order: 1g
- Purity: 99
- Supply Ability: 20tons
- CAIX Inhibitor S4
-
- $30.00 / 10BOX
-
2024-03-31
- CAS:1330061-67-0
- Min. Order: 10BOX
- Purity: 99
- Supply Ability: 20TONS
|
| | CAIX Inhibitor S4 Basic information |
| Product Name: | CAIX Inhibitor S4 | | Synonyms: | 4-[[[(3,5-Dimethylphenyl)amino]carbonyl]amino]phenyl sulfamate;CAIX Inhibitor S4;Sulfamic acid, 4-[[[(3,5-dimethylphenyl)amino]carbonyl]amino]phenyl ester;S4 >=98% (HPLC);4-(3-(3,5-Dimethylphenyl)ureido)phenyl sulfamate;CAIX Inhibitor S4, 10 mM in DMSO | | CAS: | 1330061-67-0 | | MF: | C15H17N3O4S | | MW: | 335.38 | | EINECS: | | | Product Categories: | | | Mol File: | 1330061-67-0.mol |  |
| | CAIX Inhibitor S4 Chemical Properties |
| density | 1.429±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 30 mg/ml | | pka | 8.63±0.70(Predicted) | | form | A solid | | color | White to off-white | | InChI | InChI=1S/C15H17N3O4S/c1-10-7-11(2)9-13(8-10)18-15(19)17-12-3-5-14(6-4-12)22-23(16,20)21/h3-9H,1-2H3,(H2,16,20,21)(H2,17,18,19) | | InChIKey | HGVHSNXRZYOTPD-UHFFFAOYSA-N | | SMILES | S(N)(OC1=CC=C(NC(NC2=CC(C)=CC(C)=C2)=O)C=C1)(=O)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | CAIX Inhibitor S4 Usage And Synthesis |
| Uses | S4 is a sulfamate carbonic anhydrase IX (CAIX) inhibitor in colorectal carcinoma cell lines. | | Biological Activity | S4 is a potent and selective inhibitor against sulfamate carbonic anhydrase (CA) subtypes CAIX & CAXII (Ki = 2, 7, 546, 5600 nM against human CA XII, IX, II, and I, respectively). S4 selectively inhibits migration upon anoxia/hypoxia-induced CAIX expression in cancer cultures (% inhibition/conc./cell line = 54%/100 μM/WRO, 65%/33 μM/MDA-MB-231), while exhibiting no inhibitory effects under normoxia or among non-CAIX-expressing cells (HCT116 & RT112). Daily intraperitoneal injection (10 mg/kg) is reported to reduce the metastatic tumor burden in lungs of mice bearing orthotopic eGFP-MDA-MB-231 tumors in vivo. | | in vivo | CAIX Inhibitor S4 (10 mg/kg; i.p. for 14 days) inhibits metastatic tumor burden in MDA-MB-231 model while having no effect on primary tumor growth or mouse condition[1]. | Animal Model: | Female nu/nu CBA mice (10-12 weeks) were injected with eGFP-MDA-MB-231 cells[1] | | Dosage: | 10 mg/kg | | Administration: | I.p. daily on a “5 days on, 2 days off” dosing regimen for 14 days | | Result: | Significantly reduced the metastatic tumor burden in lungs of mice bearing orthotopic eGFP-MDA-MB-231 tumors.
The average body weights between vehicle and S4 treated mice were similar throughout the experiments.
|
| | IC 50 | CA Ⅸ | | storage | Store at +4°C |
| | CAIX Inhibitor S4 Preparation Products And Raw materials |
|